Could NICE Pilot Projects Be An Opportunity For Multinationals In China’s County Hospital Market?
This article was originally published in PharmAsia News
In a bid to control overspending and improve healthcare service quality in rural areas, the Chinese government is piloting health technology assessment projects in county-level hospitals, armed with technical support from the UK’s NICE.
You may also be interested in...
China plans to issue electronic medical cards to 50% of its residents by the end of the year in a new commitment to overhaul the country's healthcare system and strengthen capacity to handle the sheer volume of Chinese patients
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.